Last reviewed · How we verify
olanzapine pamoate depot
Olanzapine pamoate depot is a long-acting intramuscular formulation of olanzapine, an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.
Olanzapine pamoate depot is a long-acting intramuscular formulation of olanzapine, an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Schizophrenia (maintenance treatment), Bipolar I disorder (maintenance treatment).
At a glance
| Generic name | olanzapine pamoate depot |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Olanzapine antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors, which reduces psychotic symptoms and stabilizes mood. The pamoate salt formulation allows for sustained release from intramuscular injection, providing therapeutic levels for extended periods (typically 2-4 weeks per injection), improving medication adherence in patients with schizophrenia or bipolar disorder.
Approved indications
- Schizophrenia (maintenance treatment)
- Bipolar I disorder (maintenance treatment)
Common side effects
- Weight gain
- Sedation
- Injection site reactions
- Hyperglycemia
- Hyperlipidemia
- Extrapyramidal symptoms
Key clinical trials
- Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer (PHASE3)
- A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication (PHASE2)
- Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients (PHASE4)
- Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms (NA)
- CATIE- Schizophrenia Trial (PHASE4)
- Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia (PHASE3)
- Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder (PHASE3)
- A Follow up Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- olanzapine pamoate depot CI brief — competitive landscape report
- olanzapine pamoate depot updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI